AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Powered by AMiner. Clicking this button will take you away from SciOpen.
Home Cancer Biology & Medicine Article
PDF (2 MB)
Cite
EndNote(RIS) BibTeX
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Original Article | Open Access

Trispecific killer engager 161519 enhances natural killer cell function and provides anti-tumor activity against CD19-positive cancers

Ying Cheng1, Xiaodong Zheng1, Xuefu Wang1, Yongyan Chen1, Haiming Wei1, Rui Sun1, Zhigang Tian1,2 ( ), Haoyu Sun1 ( )
Hefei National Laboratory for Physical Sciences at Microscale, The CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Basic Medical Sciences, Division of Life Sciences and Medicine, Institute of Immunology, University of Science and Technology of China, Hefei 230027, China
Research Unit of NK Cell Study, Chinese Academy of Medical Sciences, Beijing 100864, China
Show Author Information

Abstract

Objective

Natural killer (NK) cells have gained considerable attention due to their potential in treating “cold tumors,” and are therefore considered as one of the new strategies for curing cancer, by using worldwide development of their new possibilities and interventions with NK cell-related therapeutic products.

Methods

We constructed a trispecific killer engager (TriKE) consisting of anti-CD16, IL-15, and anti-CD19. This TriKE was designed to attract CD19+ tumor cells to CD16+ NK cells, whereas IL-15 sustained the proliferation, development, and survival of NK cells.

Results

Treatment with 161519 TriKE in the presence of CD19+ targets upregulated expression of CD69, CD107a, TRAIL, IFN-γ, and TNF-α in NK cells, and significantly improved the proliferation and cytotoxicity of NK cells. NK cells “armed” with 161519 TriKE showed stronger cytolysis against CD19+ targets compared with that of “unarmed” NK cells. A preclinical model of B-cell lymphoma in human peripheral blood mononuclear cell-reconstituted xenograft mice showed significant inhibition of tumor growth and prolonged overall survival after treatment with 161519 TriKE, when compared with that in control mice or mice treated with 1619 BiKE. Combined use of IL-2 was a more effective treatment with 1619 BiKE, when compared with that using 161519 TriKE.

Conclusions

The newly generated 161519 TriKE enhanced the proliferation, activation, cytokine secretion, and cytotoxicity of NK cells in the presence of CD19+ tumor cells. The 161519 TriKE aided inhibition of tumor growth and prolonged the overall survival of murine xenografts, and could be used to treat CD19-positive cancers.

Keywords

tumor immunotherapyNK cellTrispecific antibodytrispecific killer engager (TriKE)B-cell lymphoma

Electronic Supplementary Material

Download File(s)
cbm-17-4-1026-ESM.pdf (380.2 KB)

References

1

Thakur A, Huang M, Lum LG. Bispecific antibody based therapeutics: strengths and challenges. Blood Rev. 2018; 32: 339-47.
Crossref Google Scholar
2

Rader C. Bispecific antibodies in cancer immunotherapy. Curr Opin Biotechnol. 2019; 65: 9-16.
Crossref Google Scholar
3

Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S, et al. Tumor regression in cancer patients by very low doses of a t cell-engaging antibody. Science. 2008; 321: 974-7.
Crossref Google Scholar
4

Topp MS, Gokbuget N, Stein AS, Zugmaier G, O’Brien S, Bargou RC, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory b-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2015; 16: 57-66.
Crossref Google Scholar
5

Labrijn AF, Janmaat ML, Reichert JM, Parren P. Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019; 18: 585-608.
Crossref Google Scholar
6

Habif G, Crinier A, Andre P, Vivier E, Narni-Mancinelli E. Targeting natural killer cells in solid tumors. Cell Mol Immunol. 2019; 16: 415-22.
Crossref Google Scholar
7

Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov. 2019; 18: 197-218.
Crossref Google Scholar
8

Stojanovic A, Cerwenka A. Checkpoint inhibition: NK cells enter the scene. Nat Immunol. 2018; 19: 650-2.
Crossref Google Scholar
9

Zhang Q, Bi J, Zheng X, Chen Y, Wang H, Wu W, et al. Blockade of the checkpoint receptor tigit prevents NK cell exhaustion and elicits potent anti-tumor immunity. Nat Immunol. 2018; 19: 723-32.
Crossref Google Scholar
10

Chen YW, Tian ZG, Peng H. Immunological memory: ILC1s come into view. Cell Mol Immunol. 2019; 16: 895-6.
Crossref Google Scholar
11

Sun HY, Sun C, Xiao WH, Sun R. Tissue-resident lymphocytes: from adaptive to innate immunity. Cell Mol Immunol. 2019; 16: 205-15.
Crossref Google Scholar
12

Morvan MG, Lanier LL. NK cells and cancer: you can teach innate cells new tricks. Nat Rev Cancer. 2016; 16: 7-19.
Crossref Google Scholar
13

Hodgins JJ, Khan ST, Park MM, Auer RC, Ardolino M. Killers 2.0: NK cell therapies at the forefront of cancer control. J Clin Invest. 2019; 129: 3499-510.
Crossref Google Scholar
14

Wiernik A, Foley B, Zhang B, Verneris MR, Warlick E, Gleason MK, et al. Targeting natural killer cells to acute myeloid leukemia in vitro with a CD16 x 33 bispecific killer cell engager and ADAM17 inhibition. Clin Cancer Res. 2013; 19: 3844-55.
Crossref Google Scholar
15

Gleason MK, Ross JA, Warlick ED, Lund TC, Verneris MR, Wiernik A, et al. CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets. Blood. 2014; 123: 3016-26.
Crossref Google Scholar
16

Reusch U, Burkhardt C, Fucek I, Le Gall F, Le Gall M, Hoffmann K, et al. A novel tetravalent bispecific TandAB (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cells. MAbs. 2014; 6: 728-39.
Crossref Google Scholar
17

Vallera DA, Felices M, McElmurry R, McCullar V, Zhou X, Schmohl JU, et al. IL15 trispecific killer engagers (TriKE) make natural killer cells specific to CD33+ targets while also inducing persistence, in vivo expansion, and enhanced function. Clin Cancer Res. 2016; 22: 3440-50.
Crossref Google Scholar
18

Sarhan D, Brandt L, Felices M, Guldevall K, Lenvik T, Hinderlie P, et al. 161533 TriKE stimulates NK-cell function to overcome myeloid-derived suppressor cells in MDS. Blood Adv. 2018; 2: 1459-69.
Crossref Google Scholar
19

Schmohl JU, Felices M, Oh F, Lenvik AJ, Lebeau AM, Panyam J, et al. Engineering of anti-CD133 trispecific molecule capable of inducing NK expansion and driving antibody-dependent cell-mediated cytotoxicity. Cancer Res Treat. 2017; 49: 1140-52.
Crossref Google Scholar
20

Felices M, Kodal B, Hinderlie P, Kaminski MF, Cooley S, Weisdorf DJ, et al. Novel CD19-targeted TriKE restores NK cell function and proliferative capacity in CLL. Blood Adv. 2019; 3: 897-907.
Crossref Google Scholar
21

Gauthier L, Morel A, Anceriz N, Rossi B, Blanchard-Alvarez A, Grondin G, et al. Multifunctional natural killer cell engagers targeting NKP46 trigger protective tumor immunity. Cell. 2019; 177: 1701-13 e16.
Crossref Google Scholar
22

Bejcek BE, Wang D, Berven E, Pennell CA, Peiper SC, Poppema S, et al. Development and characterization of three recombinant single chain antibody fragments (scFvs) directed against the CD19 antigen. Cancer Res. 1995; 55: 2346-51.
Google Scholar
23

Dulson SJ, Harrington LE, Zajac AJ. Inscribing the core memories of killers. Cell Mol Immunol. 2019; 16: 104-5.
Crossref Google Scholar
24

Wang XW, Peng H, Tian ZG. Innate lymphoid cell memory. Cell Mol Immunol. 2019; 16: 423-9.
Crossref Google Scholar
25

McCall AM, Adams GP, Amoroso AR, Nielsen UB, Zhang L, Horak E, et al. Isolation and characterization of an anti-CD16 single-chain Fv fragment and construction of an anti-HER2/neu/anti-CD16 bispecific scFv that triggers CD16-dependent tumor cytolysis. Mol Immunol. 1999; 36: 433-46.
Crossref Google Scholar
26

Kipriyanov SM, Kupriyanova OA, Little M, Moldenhauer G. Rapid detection of recombinant antibody fragments directed against cell-surface antigens by flow cytometry. J Immunol Methods. 1996; 196: 51-62.
Crossref Google Scholar
27

Takeda K, Hayakawa Y, Smyth MJ, Kayagaki N, Yamaguchi N, Kakuta S, et al. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nat Med. 2001; 7: 94-100.
Crossref Google Scholar
28

Smyth MJ, Takeda K, Hayakawa Y, Peschon JJ, van den Brink MRM, Yagita H. Nature’s trail–on a path to cancer immunotherapy. Immunity. 2003; 18: 1-6.
Crossref Google Scholar
29

Li J, Piskol R, Ybarra R, Chen Y-JJ, Li J, Slaga D, et al. CD3 bispecific antibody–induced cytokine release is dispensable for cytotoxic T cell activity. Sci Transl Med. 2019; 11: eaax8861.
Crossref Google Scholar
30

Topp MS, Gokbuget N, Zugmaier G, Klappers P, Stelljes M, Neumann S, et al. Phase Ⅱ trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol. 2014; 32: 4134-40.
Crossref Google Scholar
31

Kang S, Tanaka T, Narazaki M, Kishimoto T. Targeting interleukin-6 signaling in clinic. Immunity. 2019; 50: 1007-23.
Crossref Google Scholar
32

Maude SL, Barrett D, Teachey DT, Grupp SA. Managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer J. 2014; 20: 119-22.
Crossref Google Scholar
33

Liu E, Marin D, Banerjee P, Macapinlac HA, Thompson P, Basar R, et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N Engl J Med. 2020; 382: 545-53.
Crossref Google Scholar
34

Hu Y, Tian Z, Zhang C. Natural killer cell-based immunotherapy for cancer: advances and prospects. Engineering. 2019; 5: 106-14.
Crossref Google Scholar
35

Costello RT, Fauriat C, Sivori S, Marcenaro E, Olive D. NK cells: Innate immunity against hematological malignancies? Trends Immunol. 2004; 25: 328-33.
Crossref Google Scholar
36

King DM, Albertini MR, Schalch H, Hank JA, Gan J, Surfus J, et al. Phase Ⅰ clinical trial of the immunocytokine EMD 273063 in melanoma patients. J Clin Oncol. 2004; 22: 4463-73.
Crossref Google Scholar
37

Ko Y-J, Bubley GJ, Weber R, Redfern C, Gold DP, Finke L, et al. Safety, pharmacokinetics, and biological pharmacodynamics of the immunocytokine EMD 273066 (huKS-IL2): Results of a phase Ⅰ trial in patients with prostate cancer. J Immunother. 2004; 27: 232-9.
Crossref Google Scholar
38

Waldmann TA. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat Rev Immunol. 2006; 6: 595-601.
Crossref Google Scholar
39

Sivori S, Vacca P, Del Zotto G, Munari E, Mingari MC, Moretta L. Human NK cells: surface receptors, inhibitory checkpoints, and translational applications. Cell Mol Immunol. 2019; 16: 430-41.
Crossref Google Scholar
Cancer Biology & Medicine
Volume 17 Issue 4,
November 2020
Pages 1026-1038
DOI: 10.20892/j.issn.2095-3941.2020.0399
Cite this article:
Cheng Y, Zheng X, Wang X, et al. Trispecific killer engager 161519 enhances natural killer cell function and provides anti-tumor activity against CD19-positive cancers. Cancer Biology & Medicine, 2020, 17(4): 1026-1038. https://doi.org/10.20892/j.issn.2095-3941.2020.0399

60

Views

3

Downloads

31

Crossref

N/A

Web of Science

29

Scopus

Altmetrics
Received: 15 July 2020
Accepted: 29 October 2020
Published: 15 November 2020
©2020 Cancer Biology & Medicine.

Creative Commons Attribution-NonCommercial 4.0 International License
Return